Additionally, DDX60 favored its expression in mesenchymal and classical subtype (Figure 1C and Supplementary Figure 1E), MGMT unmethylated (P < 0.001, Figure 1D), ATRX wild-type (P < 0.001, Figure 1E), TERT promoter mutated (P < 0.001, Figure 1F), and IDH wild-type gliomas (P < 0.001, Figure 1G, Supplementary Figure 1F). The gene discussed is ATRX; the disease is central nervous system cancer.